Cancer Family
Neoplasm
CI-CAN-00000001Explore in graph →
Non-malignant22,971 active trials259 approved drugs4,031 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000001Explore in graph →
Clinical trials
105,884 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07586202 | A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC(AmiNA) | recruiting | Phase 2 | 68 | Janssen Research & Development, LLCINDUSTRY | 6 | Sep 25, 2026 | clinicaltrials |
| NCT07630974 | A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01) | recruiting | Phase 1 / Phase 2 | 134 | Merck Sharp & Dohme LLCINDUSTRY | 10 |
| Sep 25, 2026 |
| clinicaltrials |
| NCT07634471 | A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007) | recruiting | Phase 2 / Phase 3 | 960 | Merck Sharp & Dohme LLCINDUSTRY | 9 | Sep 25, 2026 | clinicaltrials |
| NCT07670312 | Evaluation of XYA02 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 190 | XYone Therapeutics, IncINDUSTRY | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07673341 | [18F]FTT Positron Emission Tomography/Computed Tomography to Predict Treatment Response in Patients Scheduled to Receive Gemcitabine, Cisplatin, and Durvalumab for Newly Diagnosed Cholangiocarcinoma | recruiting | Phase 2 | 22 | University of WashingtonOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07686367 | Testing the Anti-Cancer Drug, Brenetafusp (IMCF106C), in Rare Cancers | not yet recruiting | Phase 2 | 42 | National Cancer Institute (NCI)NIH | 0 | Sep 25, 2026 | clinicaltrials |
| NCT07832292 | A Study of JNJ-101556143 in Participants With Metastatic Prostate Cancer | recruiting | Phase 2 | 100 | Janssen Research & Development, LLCINDUSTRY | 2 | Sep 25, 2026 | clinicaltrials |
| NCT07840456 | Safety and Efficacy of Ruxolitinib in Patients With HNSCC and High NLR Treated With Pembrolizumab - The Phase 2 InflammaSTOP Trial(InflammaSTOP) | not yet recruiting | Phase 2 | 66 | University Hospital, Basel, SwitzerlandOTHER | 2 | Sep 25, 2026 | clinicaltrials |
| NCT07840677 | Tafolecimab Combined With Chemoimmunotherapy as Neoadjuvant Treatment for pMMR/MSS Locally Advanced Colon Cancer(TRIUNITE-08) | recruiting | Phase 2 | 70 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07841106 | Early Prophylactic Versus Late Salvage Recombinant Human Endostatin in Managing Radiosurgery-Induced Brain Injury for NSCLC Brain Metastases. | not yet recruiting | Phase 2 | 49 | Jiangmen Central HospitalOTHER | 0 | Sep 25, 2026 | clinicaltrials |
| NCT07841236 | ctDNA-Guided Immunotherapy for dMMR/MSI-H Colon Cancer | recruiting | Phase 2 | 23 | Fudan UniversityOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07841574 | HAIC Plus QL1706 & Bevacizumab in Unresectable HER2-Negative ICC | recruiting | Phase 2 | 35 | Lianghe LuOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07841873 | Zanidatamab Combined With Liposomal Irinotecan and Capecitabine for Second-line Treatment of HER2-positive Unresectable Biliary Tract Tumors(ZENITH-01) | not yet recruiting | Phase 2 | 15 | Anhui Provincial HospitalOTHER_GOV | 0 | Sep 25, 2026 | clinicaltrials |
| NCT07841925 | A Study of BL-M08D in Patients With Locally Advanced or Metastatic Melanoma and Other Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 30 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07842198 | Restrictive Versus Standard Antibiotic Treatment During CAR-T Therapy(CARMic) | not yet recruiting | Phase 2 | 150 | Zealand University HospitalOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07842276 | Utidelone Capsules Combined With Doxorubicin for Advanced Soft Tissue Sarcoma | not yet recruiting | Phase 2 | 49 | Beijing Biostar Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07842471 | Local Consolidative Therapy Versus Maintenance Immunotherapy After First-Line Chemoimmunotherapy in Metastatic NSCLC | not yet recruiting | Phase 2 | 117 | Guangdong Provincial People's HospitalOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT00295893 | Combination Chemotherapy With or Without Trastuzumab in Treating Patients With Stage II or Stage III Breast Cancer | active not recruiting | Phase 2 | 121 | City of Hope Medical CenterOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT01511562 | Combination Chemotherapy With or Without Autologous Stem Cell Transplant in Treating Patients With Central Nervous System B-Cell Lymphoma | completed | Phase 2 | 113 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT02860000 | Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer | completed | Phase 2 | 96 | Mayo ClinicOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT02940301 | Ibrutinib and Nivolumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma | active not recruiting | Phase 2 | 18 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT02974647 | Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma | recruiting | Phase 2 | 83 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT03191149 | Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change | recruiting | Phase 2 | 46 | National Cancer Institute (NCI)NIH | 1 | Sep 24, 2026 | clinicaltrials |
| NCT03573648 | Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer(ImmunoADAPT) | active not recruiting | Phase 2 | 33 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT03618550 | Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma | recruiting | Phase 2 | 257 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT03661307 | Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome | recruiting | Phase 1 / Phase 2 | 73 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT03986034 | Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) | recruiting | Phase 2 | 75 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Sep 24, 2026 | clinicaltrials |
| NCT04083495 | CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma | recruiting | Phase 2 | 20 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT04115761 | Evaluate the Efficacy and Safety of ADCV01 as an Add-On Treatment for Primary Glioblastoma Multiforme (GBM) Patients | recruiting | Phase 2 | 24 | Ever Supreme Bio Technology Co., Ltd.INDUSTRY | 1 | Sep 24, 2026 | clinicaltrials |
| NCT04224272 | Phase 2a Study of ZW25 in Combination With Palbociclib Plus Fulvestrant | completed | Phase 2 | 51 | Jazz PharmaceuticalsINDUSTRY | 3 | Sep 24, 2026 | clinicaltrials |
| NCT04340882 | Phase 2 DoceRamPem for Patients With Metastatic or Recurrent NSCLC Who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade(DoceRamPem) | active not recruiting | Phase 2 | 30 | Emory UniversityOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT04414163 | A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type | active not recruiting | Phase 2 | 23 | ImmuneOncia Therapeutics Inc.INDUSTRY | 1 | Sep 24, 2026 | clinicaltrials |
| NCT04417062 | Olaparib With Ceralasertib in Recurrent Osteosarcoma | active not recruiting | Phase 2 | 49 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT04489771 | A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013) | completed | Phase 2 | 154 | Merck Sharp & Dohme LLCINDUSTRY | 9 | Sep 24, 2026 | clinicaltrials |
| NCT04570956 | Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia, Lobular Carcinoma In Situ, or Increased Breast Cancer Risk | terminated | Phase 2 | 65 | Mayo ClinicOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT04584255 | Niraparib + Dostarlimab In BRCA Mutated Breast Cancer | active not recruiting | Phase 2 | 66 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT04590326 | A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab | recruiting | Phase 1 / Phase 2 | 612 | Regeneron PharmaceuticalsINDUSTRY | 5 | Sep 24, 2026 | clinicaltrials |
| NCT04669808 | Open Label, Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With Basal Cell Carcinoma | completed | Phase 2 | 32 | SirnaomicsINDUSTRY | 1 | Sep 24, 2026 | clinicaltrials |
| NCT04728893 | Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) | recruiting | Phase 2 | 490 | Merck Sharp & Dohme LLCINDUSTRY | 22 | Sep 24, 2026 | clinicaltrials |
| NCT04840602 | Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma | recruiting | Phase 2 | 92 | National Cancer Institute (NCI)NIH | 1 | Sep 24, 2026 | clinicaltrials |
| NCT04844073 | A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer | terminated | Phase 1 / Phase 2 | 95 | TakedaINDUSTRY | 4 | Sep 24, 2026 | clinicaltrials |
| NCT04981899 | A Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab at the Fixed Dose 40 mg, Ifosfamide, Carboplatin, Etoposide (NICE-40) in Patients With Relapsed/Refractory Hodgkin Lymphoma(NICE-40) | active not recruiting | Phase 1 / Phase 2 | 30 | St. Petersburg State Pavlov Medical UniversityOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT05118789 | A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1) | recruiting | Phase 1 / Phase 2 | 359 | Nuvalent Inc.INDUSTRY | 14 | Sep 24, 2026 | clinicaltrials |
| NCT05241860 | Testing Interruption of Hormonal Medications in Patients Responding Exceptionally to Therapy for Metastatic Prostate Cancer, (A-DREAM)(A-DREAM) | active not recruiting | Phase 2 | 79 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT05444998 | Neoadjuvant Inetetamab and Pyrotinib and Nab-paclitaxel for HER2+Breast Cancer | completed | Phase 2 | 20 | Xijing HospitalOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT05635734 | Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma | completed | Phase 1 / Phase 2 | 33 | Cantex PharmaceuticalsINDUSTRY | 1 | Sep 24, 2026 | clinicaltrials |
| NCT05640999 | Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER | recruiting | Phase 2 | 393 | Canadian Cancer Trials GroupNETWORK | 9 | Sep 24, 2026 | clinicaltrials |
| NCT05708235 | A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC Population(MiRaDoR) | active not recruiting | Phase 2 | 976 | MedSIROTHER | 2 | Sep 24, 2026 | clinicaltrials |
| NCT05748171 | A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL | recruiting | Phase 2 | 100 | PfizerINDUSTRY | 15 | Sep 24, 2026 | clinicaltrials |
Data updated 6 days agoSource updated Sep 25, 2026source: clinicaltrials